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Abstract: Aims: This study aims to identify differences in parental satisfaction between three distinct types of intensive 
insulin therapies used for children with type 1 diabetes (T1D) namely multiple daily injection (MDI), continuous subcutaneous 
insulin infusion (CSII) and flexible multiple daily injection (fMDI). Materials and Methods: Data was collected over a 6-month 
period during the quarterly clinic visits. Two modified versions of validated tools- Insulin Treatment Satisfaction Questionnaire 
(ITSQ) and Diabetes Treatment Satisfaction Questionnaire (DTSQ), were electronically filled in by the parents of children 
with T1D. This provided information on parental satisfaction on the following areas: inconvenience of regimen, lifestyle 
flexibility, impression of glycaemic control, fear of hypoglycaemia, diabetic symptoms, treatment barriers, worry, treatment 
adherence and communication. Results: 34 parents completed the electronic data forms on iSurvey. Parents of the fMDI group 
were the most confident to avoid severe hypoglycaemia whereas MDI-parents being the least confident, t (21) = 2.12, p = 
0.046. There was no statistical difference noted on how confident parents felt to avoid asymptomatic hypoglycaemia, their 
worry about nocturnal hypoglycaemia, convenience and ease of using insulin in public places, nor was there statistically 
significant difference in the pain and discomfort felt by their children. Parents of children with fMDI felt the time their children 
spent with hyperglycemia was higher than the MDI, t (21) = 2.11, p = 0.047. Parents of the CSII group were most likely to 
continue their current treatment and were also, most likely to recommend the treatment regimen to others. Parents of MDI were 
least likely to do so, t (20) = 2.12, p =.047 and t (18) = 2.35, p = 0.031. Conclusion: Although this study was conducted with a 
very small sample size, it has revealed no significant difference in parental satisfaction among MDI, CSII and fMDI groups 
including parental anxiety and stress, ease of use in public places, convenience, flexibility, parental perception of pain and 
discomfort experienced by their children and fear of nocturnal hypoglycaemia. However, parents indicated greater confidence 
in avoiding severe hypoglycaemia in fMDI albeit there was higher glycaemic variability. Parents with CSII were more satisfied 
with treatment and more likely to recommend their current treatment option to others, than fMDI and MDI, as the preferred 
mode of treatment. 
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1. Introduction 
These are exciting times in the realm of management of 
type 1 diabetes (T1D), One of the most common chronic 
medical conditions affecting children and young adults with a 
worldwide prevalence of nearly half a million children below 
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14 years (International Diabetes Federation, 2013). [1] 
Poorly controlled T1D can be life- threatening and eventually 
lead to long term microvascular complications such as 
retinopathy and nephropathy. The availability of evolving 
technologies such as flash glucometer, continuous glucose 
monitoring systems, devices with reduced need for insulin 
injection prick (e.g. i-port advance), sensor augmented 
insulin pump, artificial pancreatic system and different types 
of insulin analogues, are continuously changing the way T1D 
is treated, impacting variable treatment satisfaction. 
Emerging insulin delivery and glucose monitoring systems 
aiming for a better glycemic control, can often be 
counterproductive due to the significant overload of digital 
information. Families with various affective, behavioral, and 
cognitive characteristics may derive different benefit from a 
specific type of insulin regimen. 
Diagnosis of T1D in children is a life changing event for 
the entire family with profound impact on emotional 
wellbeing and quality of life (QoL) for both children and 
their parents. The mainstay of the treatment of T1D today is 
the intensive insulin therapy delivered either by continuous 
subcutaneous insulin infusion (CSII) or multiple daily 
injections- by fixed dose (MDI) or by flexible dose adjusted 
to carbohydrate intake (fMDI). Twice-daily insulin regimen 
(BD) has largely been made obsolete because of outcome 
data on microvascular complications from the landmark 
Diabetes Control and Complication Trial. [2] A flexible 
version of multiple daily injection, fMDI is currently gaining 
popularity with distinct advantage of better meal quality 
flexibility requiring to inject variable doses of insulin based 
on the carbohydrate intake. The overall decision while 
selecting the right insulin treatment strategy and glucose 
monitoring system should not only depend on glycemic 
control but also to the QoL and treatment satisfaction for 
both parents and children. In terms of controlling T1D, type 
of intensive insulin regimen is relevant. One meta-analysis of 
the seven RCTs involving 220 children with T1D 
demonstrated that CSII was associated with statistically 
significant, but, only with marginal decrease in HbA1c level 
(MD = -0.24%, 95% CI = -0.41 to -0.07) compared to MDI. 
This meta-analysis demonstrated no significant differences in 
episodes of severe hypoglycemia (SH) and diabetic 
ketoacidosis (DKA) compared to MDI [3]. The largest study 
in this regard was the SWEET (Better control in Pediatric 
and Adolescent diabeteS: Working to crEate CEnTers of 
Reference) registry which compared glycemic control 
between patients treated with CSII vs MDI. The SWEET 
study included 16,570 children with T1D and showed that 
both HbA1c and daily insulin dose (U/kg/d) remained 
decreased in children treated with CSII compared to MDI (P 
<.0001). [4] Other studies demonstrated that CSII is 
associated with equivalent short term but significantly 
improved sustained glycemic control, especially in preschool 
children in motivated families, with higher treatment 
satisfaction and improved QoL for children. [5] [6] In a 
systematic review, parental QoL was reported in two out of 
seven studies, with one study reporting no significant 
improvement in CSII group compared to MDI but the other 
reported significant reduction in diabetes-related worry in 
CSII and increased frequency of stress in MDI. [3] Some of 
the factors that may potentially influence parental satisfaction 
and QoL include age of their children, duration of T1D, 
presence of comorbidities, type of insulin regime and 
delivery (pen vs syringe and needle), associated use of CGM, 
type of insulin (analogue vs human), presence of sensors 
augmentation in the pump, previous history of severe 
hypoglycemia, parental fear of hypoglycemia, additional 
requirement of carbohydrate counting and supportive school 
environment. In this study we focused on the impact of types 
of insulin regimen on the parental treatment satisfaction. 
Although comparison of MDI and CSII on parental 
satisfaction has been studies, data comparing fMDI with 
other two is lacking. The aim of this study was also to 
identify additional considerations when recommending the 
most appropriate regimen of treatment in T1D. 
2. Materials and Methods 
2.1. Participants 
Parents of children with T1D who are using one of three 
types of insulin regimen; CSII, MDI and fMDI. 
2.2. Procedure 
This survey-based study was conducted in the north west 
region of Tasmania, with the approval of, and, in accordance 
with the policies and procedures of the University of 
Tasmania Health and Medical Human Research Ethics 
Committee. A self-report questionnaire along with modified 
version of Insulin Treatment Satisfaction Questionnaire and 
Diabetes Treatment Satisfaction Questionnaire were created 
on an electronic tablet using iSurvey application. The de-
identified information was then collected electronically 
before downloading into an excel spreadsheet and SPSS 
V24.0 for further analysis. 
2.3. Materials 
The questionnaire was divided into four main sections: 
2.3.1. Demographics and General Questions 
This 20-item questionnaire was completed by parents and 
included their demographic information and the medical 
history of the child. 
2.3.2. The Insulin Treatment Satisfaction Questionnaire 
(ITSQ; Anderson et al) 
This is a 22-item questionnaire designed to measure 
treatment satisfaction for individuals with diabetes treated 
with insulin. The questionnaire was amended to assess 
treatment satisfaction perceived by the parents. The ITSQ 
consists of five satisfaction domains: Inconvenience of 
regimen (5 items); Lifestyle flexibility (3 items); Glycemic 
control (3 items); Hypoglycemic control (5 items) and 
Insulin delivery device (6 items). Items are measured on a 
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7-point Likert scale where lower scores indicate greater 
confidence (1= extremely convenient to 7 = not at all 
convenient). Questionnaire items are transformed to a scale 
of 0-100 with higher scores indicating better treatment 
satisfaction. For each subscale, the sum score is divided by 
number of items. 
2.3.3. Diabetes Treatment Satisfaction Questionnaire 
(DTSQ) 
This 8-item questionnaire was completed by parents to 
evaluate their satisfaction with the current diabetes 
treatment regimen for their child. The questions were 
adapted from a previously validated questionnaire 
(Bradley & Bradley, 1994). The DTSQ measures overall 
satisfaction, convenience, flexibility, understanding of 
diabetes, willingness to recommend current treatment and 
to continue current treatment. Each item is rated on a 7-
point Likert scale where higher scores indicate greater 
levels of satisfaction (0 = ‘very dissatisfied’ to 6 = ‘very 
satisfied’). Items two and three assess glycemic control 
and are rated differently (0 = ‘never’ to 6 = ‘most of the 
time’). All items except items 2 and 3 are summed to 
produce a total score (0-36). Higher scores indicate higher 
treatment satisfaction. 
3. Results 
3.1. Demographics and General Questions 
A total of 35 parents of children with T1D were enrolled 
for the study during their quarterly clinic visit. One withdrew 
before administering the questionnaire due to time constraint. 
Twenty of them were between 30-49 years age. Only two 
parents were of aboriginal Australian descent. Most of the 
respondents were employed either, in fulltime or casual jobs. 
Nearly one third of all respondents were either, an advanced 
diploma holder or above. Fifty percent of the parents were 
married. Table 1, shows the demographic information for the 
parents. The study group, (see Table 2), indicated only 10 % 
of all the children with T1D were below 8 years old. Overall, 
there were an equal number of boys and girls. Three in every 
four children had acceptable BMI and 5% were obese. In this 
cohort, half of all children had poor glycemic control as 
defined by HbA1c being above 9%, possibly due to a high 
proportion of adolescents. 14 children were using MDI 
(14/35) followed by 11children who were on CSII (11/35) 
and the least number of children, 10 were administering 
fMDI (10/35) in this cohort. (Figure 1) The treatment 
modality for each child had been selected by the treating 
pediatricians as per the child’s clinical needs and in 
consultation with the family. Fourteen children (40%) had 
previously switched from MDI to a different type of insulin 
regimen (fMDI or CSII). Insulin Glargine, as a long acting 
and Insulin aspart and lispro as short-acting insulin analogue 
delivered through the pen device for both fMDI and MDI 
regimen. Insulin aspart was used for all the children with 
CSII in our cohort. 
 
Figure 1. The pie chart showing the proportion of the children and 
adolescents being treated by CSII, MDI and fMDI. 
Table 1. Demographic Information of Parents of Children with Type 1 
Diabetes.  
Variables  n = 34  
Age    
18-29  5  
30-49  20  
50-64  8  
65+  1  
Education    
Less than year 12 or equivalent  8  
Year 12 or equivalent  4  
Certificate  11  
Advanced Diploma/Diploma  3  
Bachelor’s Degree  3  
Grad Dip/Grad Cert  3  
Master’s Degree  2  
Ethnicity    
Australian 31  
Torres Strait Islander/Aboriginal 1 
Australian Aboriginal 2  
Employment Status   
Casual employment  7  
Full-time employment  9  
Home duties  8  
Part-time employment  9  
Unemployed  1  
Marital Status   
Defacto  4  
Divorced  6  
Married  17  
Single-never married  7  
3.2. Insulin Treatment Satisfaction Questionnaire 
The modified version of this validated questionnaire was 
to determine the satisfaction of the child’s insulin treatment, 
as perceived by their parents. The means and standard 
deviations are presented in Table 3. Overall, parents indicated 
that they were “confident” that their child could avoid 
symptoms of overall hypoglycemia. Parents with fMDI felt 
most confident with their child being able to avoid severe 
hypoglycemia that could result in loss of consciousness, in 
comparison to the least confident group of ‘MDIs’, t (21) = 
2.12, p =.046. Parents were “somewhat worried” in relation 
to their child experiencing nocturnal hypoglycemia. There 
was, however, no statistically significant difference noted 
between the treatment regimen with the most worry (fMDI) 
and the least worry (MDI), t (19) = 1.02, p = 0.323. The 
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overall ease of current insulin regimen was reported “very 
easy” and there was again, no significant statistical difference 
noted between the treatment regimen with the most ease 
(fMDI) with the least ease (MDI), t (18) = 0.42, p = 0.678. 
Parents reported their children’s overall convenience of 
taking insulin when away from home as “very convenient” 
and there was no significant difference noted between the 
treatment regimen with the most convenience (MDI) and 
with the least convenience (CSII), t (21) = 1.82, p = 0.084. 
Parents perceived the pain and discomfort experienced by 
their children (for all?) as “mild” and there was no significant 
difference noted between the regimen causing most pain and 
discomfort (CSII) and least pain and discomfort (fMDI), t 
(15) = 1.54, p = 0.145. Most parents felt “somewhat 
comfortable” in their child’s level of comfort while taking 
insulin in a public place and there was no statistical 
difference noted between the treatment regimen perceived to 
be most comfortable (CSII) and with the least comfortable 
(MDI), t (22) = 1.62, p = 0.119. The amount of emotional 
distress or anxiety reported by parents on behalf of their 
child, overall, was “mild” and there was no significant 
difference noted between the treatment regimen with the 
most emotional distress or anxiety (CSII) and with the least 
emotional distress or anxiety (fMDI), t (14) = 1.80, p = 
0.093. 
3.3. Diabetes Treatment Satisfaction Questionnaire 
The modified version of this validated questionnaire was 
to determine the satisfaction with the child’s overall diabetes 
regimen of treatment, as perceived by their parents. The 
means and standard deviations are presented in Table 4. It 
was reported that overall, parents were “satisfied” with their 
child’s current treatment and there was a significant 
difference noted between the treatment regimen with the 
most satisfaction (fMDI) and the treatment regimen with the 
least satisfaction (CSII), t (14) = 2.56, p = 0.022. The parents 
reported, overall, that they felt their child experienced 
hyperglycemia “some of the time” and there was a significant 
difference noted between the treatment regimen with the 
most time with hyperglycemia (fMDI) and with the least time 
with hyperglycemia (MDI), t (21) = 2.11, p = 0.047. Parents 
reported, that they felt their child experienced hypoglycemia 
“not a lot of the time”. There was again, a significant 
difference noted between the treatment regimen with the 
most time with hypoglycemia (fMDI) and least time with 
hypoglycemia (MDI), t (21) = 2.58, p = 0.018. The 
convenience of the treatment regimens overall was rated as 
“somewhat convenient” by the parents. There was no 
statistically significant difference noted between the 
treatment regimen identified as providing the most 
convenience (CSII) and the least convenience (fMDI), t (19) 
= 0.268, p = 0.791. Parents rated their child’s treatment 
overall as “flexible”. There was no significant difference 
noted between the treatment regimen identified as providing 
the most flexibility (MDI) and with the least flexibility 
(fMDI), t (18) = 0.71, p = 0.484. When asked if the parents 
would recommend their child’s treatment regimen, the 
consensus was “I would most likely recommend”. There was, 
however, a significant difference noted between the treatment 
regimen with the most recommendation value (CSII) and the 
treatment regimen with the least recommendation value 
(MDI), t (18) = 2.35, p = 0.031. Finally, parents indicated, 
overall, that they would be “mostly satisfied” to continue 
with their child’s current treatment regimen. There was, 
however, a significant difference noted between the treatment 
regimen which they would most likely to continue (CSII) vs 
least likely to continue (MDI), t (20) = 2.12, p = 0.047. 
4. Limitations 
1. Small sample size. 
2. Not being able to utilize an appropriate ‘purpose-built’ 
validated tool to capture parental satisfaction. No validated 
tool was available to assess the satisfaction of parents whose 
children were treated for T1D. We used modified version of 
ITSQ and DTSQ to capture the parents’ perspective about 
their children’s treatment regimen. 
However, the WEll-being and Satisfaction of CAREgivers 
of Children with Diabetes Questionnaire-WE-CARE, has 
recently been developed which is going through additional 
validation processes. (7). 
3. Modes of glucose estimation were not looked at. 
Children were using different glucose monitoring strategies 
like finger-prick glucometer, flash glucometer, CGM- all of 
which have the potential to influence parental satisfaction. 
4. Potential for selection bias- Parental cognitive and 
socioeconomic characteristics influence the decision made 
regarding the type of insulin therapy regimen being selected 
(i.e., availability of private health insurance, parental 
education and motivation etc.). 
Table 2. Demographic Information of Children with Type 1 Diabetes. 
Variables  n = 35  
Age    
2-4 2  
5-8  1  
9-12  12  
13-18  19  
Gender   
Female  18  
Male  17  
BMI    
11-15  1  
16-20  17  
21-25  9  
26-30  6  
>30  2  
HbA1C    
>9.0 %  15  
8.6% - 9.0%  7  
8.1% - 8.5%  3  
7.6% - 8.0%  5  
6.5% - 7.5%  4  
< 6.5% 1  
Current Treatment   
Insulin Pump (CSII)  11  
Flexible Insulin Dosing (fMDI)  10  
Multiple Daily Injections (MDI)  14  
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5. Discussions 
The prevalence of T1D in Australia is 139 cases per 
100,000 population placing it as the 10th highest among the 
34 OECD countries. Fortunately, the incidence rate of T1D 
has not risen in Australia over the last 15 years. Tasmania has 
the highest prevalence of T1D in children among all the 
Australian states, being 166 per 100,000 population. [1] Our 
study was conducted in a regional center in Tasmania and its 
demographic characteristics were overall similar with the 
national average as per the Australian Institute of Health and 
Welfare, 2013 report. T1D were similar for both boys and 
girls. Incidence rates for children aged 10– 14years were 10 
times higher than rates for children aged 0–4years. 
Nationally, just over 2 in 5 children (43%) with T1D used 
CSII to administer insulin, as opposed to one-third in our 
cohort. This may be reflective of the lower socioeconomic 
population within our region with less access to private 
health insurance. 
Over time, insulin treatment regimen has changed 
worldwide with the primary aim to improve glycemic 
control. In MDI, fixed dose long-acting basal insulin 
injection is given separately, in addition to the fixed 
number of meal-time boluses. A meal bolus should be given 
ideally 15 minutes before meals. When compared to MDI, 
CSII offers added advantage requiring less injection prick 
(1 x every 2-3 days) but more importantly, can give 
variable basal rate to match the physiological pattern. 
Correction dose can also be given without an extra injection. 
Not everyone with T1D wishes to undertake CSII or does 
not have the financial means to do so. Flexible multiple 
daily injection (fMDI), has been developed as an alternative 
means of delivering intensive insulin therapy. This regimen 
involves insulin delivered in a dose specific to the amount 
of carbohydrate intake during meal. A study in the UK 
suggested that the training promoting dietary freedom 
involving carbohydrate counting is effective in improving 
QoL and glycemic control in people with T1D without 
increasing severe hypoglycemia. [8] In another study in 
2002, at the Children’s Hospital of Wisconsin Diabetes 
Center, USA, demonstrated a significant improvement in 
HbA1c in prepubertal (9.3%±1.3% vs. 8.0%±1.1%, 
p<0.002) and pubertal subjects (9.2%±1.0% vs. 8.2%±0.9%, 
p<0.001) with fMDI compared to the conventional therapy. 
Most importantly, the rate of severe hypoglycemia was 
decreased in both prepubertal (p<0.01) and pubertal 
(p<0.05) groups. [9] Our study echoed similar findings 
from a parents’ perspective- parents of children using fMDI 
were more confident in avoiding severe hypoglycemia in 
their children. However, there was higher episodes of 
asymptomatic hypoglycemia and higher glycemic 
variability in this group than MDI or CSII. This higher 
variability associated with fMDI is likely due to 
inconsistent carbohydrate counting leading to improper 
meal-time dose adjustment or not consuming all 
carbohydrates bloused for. 
Selecting the right insulin therapy is often quite 
challenging. There is a need for an ideal insulin regimen that 
is less restrictive and burdensome with lower risk of 
hypoglycemia, especially severe hypoglycemia, which can be 
life-threatening. Despite the availability of three distinct 
types of insulin therapy, glycemic control largely remains 
suboptimal in Pediatric populations among adolescents. This 
is likely due to nonadherence and lack of meal-time dose 
adjustment. In a multicentric survey-based study among 
physicians and patients, in the USA, it was found that nearly 
one third of patients reported insulin omission at least 1 day 
in the previous month, with an average of 3.3 days insulin 
omission. Three quarters of physicians reported a mean of 4.3 
days per month of basal insulin omission and 5.7 days per 
month of meal-time insulin omission. Patients and providers, 
in this study, indicated that the five most common reasons for 
insulin non-adherence were: being too busy, travelling, 
skipped meals, stress⁄ emotional problems and public 
embarrassment. [10] Our study identified that there is little 
difference between the three types of insulin therapy 
regarding parental stress and anxiety, fear of asymptomatic 
hypoglycemia, convenience of taking insulin when away 
from home and ease of use without any significant pain and 
discomfort. Most physicians report that many insulin-treated 
patients do not have adequate glucose control (87.6%) and 
that they would treat more aggressively if there was no 
concern about severe hypoglycemia (75.5%). In this regard, 
our study added value suggesting the selection of fMDI may 
be more appropriate as more parents in this group indicated 
they had more confidence in avoiding severe hypoglycemia. 
[10] Higher frequency of severe hypoglycemia often leads to 
over-treated hyperglycemia and higher variability, therefore, 
poor overall glycemic control. Psychosocial screening has 
been recommended for pediatric patients with newly 
diagnosed T1D and their families. This is a feasible tool to 
identify families at risk for early emerging complications and 
nonadherence. [11] As previously discussed one of the most 
important stressors related to diabetic treatment is the fear of 
hypoglycemia. In a cross-sectional, population-based study 
on the parents of 325 children with T1D it was found that the 
parents with the highest levels of fear of hypoglycemia had 
higher number of children with reduced QoL (P < 0.001). 
Likewise, higher episodes of severe hypoglycemia were 
associated with an increased fear of hypoglycemia for the 
parents (P = 0.004). The insulin regimen with a greater 
chance of avoiding severe hypoglycemia in these families 
may improve their confidence and treatment satisfaction. 
[12]. 
Various insulin regimen brings different challenges to 
family life. Carbohydrate counting, for example, is an 
extremely important component of good T1D management 
and is a definite requirement for fMDI and CSII to be 
successful. [13] Carbohydrate counting can be considered 
as an added cognitive and affective challenge to the family. 
Our study indicated that overall the parents felt their 
children tolerated the insulin therapy well with minimal 
pain and discomfort without any difference among the 
various types of insulin therapy. Parents were overall 
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“satisfied” with their child’s current treatment and found the 
current insulin regimen was convenient and flexible. 
Interestingly, parents with fMDI were found to be more 
satisfied than others, however, parents of CSII group were 
more likely to recommend to others, potentially reflecting a 
selection bias. In a similar comparative study conducted in 
UAE, about the treatment satisfaction and health perception 
in children and adolescents with T1D on MDI, CSII and 
sensor-augmented pump therapy, it was found that CSII 
users had a higher treatment satisfaction and better health 
perception than those on MDI. Authors concluded that 
augmenting pump therapy with sensor use added value to 
treatment satisfaction without correlation with the duration 
of the sensors use. [14] fMDI was not compared in the 
study. In addition to the types of insulin regimen and 
delivery systems, other factors which potentially impact 
parental satisfaction include the method of administration 
of MDI, presence of CGM, sensor augmented pump 
systems and artificial pancreatic system (closed loop 
system). In a multicenter, randomized, controlled, cross-
over study, it was demonstrated that adding CGM to pump 
therapy significantly improves metabolic control but found 
no significant impact on the overall health related QoL in 
children. [15] Parental satisfaction was not assessed. 
Similarly, compared to the vial and syringe method of 
insulin administration, pens provide more accurate dosing - 
which is particularly important in children - thereby 
improving short-term and potentially long-term outcomes, 
parent’s confidence and satisfaction. [16] The artificial 
pancreatic system is a revolutionized concept and is 
expected to improve parental satisfaction as well as, 
glycemic control. Experiences of parents of 5-8-year-old 
children with T1D participating in a clinical trial on the use 
of artificial pancreas (AP) suggests a strong likelihood of 
future parental acceptance. [17] An extension of our study 
in the future comparing the AP with other modes of 
intensive insulin therapy would be very intriguing. It should 
be noted that types of insulin can also play an important 
role in parental satisfaction. Insulin detemir, for instance, is 
a basal insulin analogue that causes less weight gain than 
other basal insulin formulations, including the intermediate-
long acting Neutral Protamine Hagedorn (NPH) insulin.(18) 
Parents also preferred prandial insulin Aspart for MDI in 
pre-school children than NPH.(19) In another study 
comparing CSII and MDI using insulin Aspart with MDI 
using Human Insulin, it was found all metabolic control 
parameters remained unchanged and equivalent, but most 
importantly caregiver treatment satisfaction was higher in 
parents who chose insulin Aspart containing CSII therapy. 
(20) A telephone-based intervention focusing on child 
development, coping, and problem-solving skills has the 
potential to positively impact parents' QoL and may have 
implications for improving children's health as well as their 
QoL. [21]. 
Table 3. Insulin Treatment Satisfaction Questionnaire Results. 
Item  
Overall 
Flexible Insulin 
Dosing 
Multiple Daily 
Insulin (MDI) 
Insulin Pump 
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
How confident are you that your child can avoid symptoms of 
low blood sugar with their current insulin treatment?  
34 2.7 (1.7) 10 3.1 (1.6) 14 2.1 (1.4) 11 3.2 (1.8) 
How confident are you that your child can avoid severe episodes 
of low blood sugar that result in loss of consciousness with the 
insulin they currently use? *  
34 2.3 (1.4) 10 2.8 (1.1) 14 1.7 (1.3) 11 2.5 (1.4) 
How worried are you about your child experiencing low blood 
sugar during the night with the insulin that they currently use?  
34 3.2 (1.5) 10 3.5 (1.6) 14 2.8 (1.5) 11 3.4 (1.4) 
How easy is it for your child to take the correct amount of 
insulin each time with the insulin they currently use?  
34 2.4 (1.6) 10 2.3 (0.8) 14 2.5 (1.8) 11 2.5 (1.9) 
How convenient is your child’s current method of taking insulins 
when they are away from home?  
34 2.3 (1.5) 10 2.2 (0.8) 14 2.8 (1.9) 11 1.6 (1.3) 
How much pain or other physical discomfort do you think your 
child experiences with their current method of taking insulin?  
34 3.0 (1.3) 10 2.7 (1.3) 14 2.8 (1.6) 11 3.5 (0.8) 
How comfortable do you think your child is while taking insulin 
in a public place (where people might see them) with their 
current method of taking insulin?  
34 3.1 (2.0) 10 2.8 (1.5) 14 3.9 (2.1) 11 2.5 (2.0) 
How much emotional distress or anxiety do you experience 
related to your child’s method of taking insulin?  
34 3.1(1. 7) 10 2.4 (0.8) 14 3.3 (2.0) 11 3.5 (1.9) 
 
6. Conclusion 
The study did not find any statistically significant 
difference between the insulin regimens regarding parental 
perception of their children’s asymptomatic daytime and 
nocturnal hypoglycemic episodes, ease of use, flexibility and 
convenience, pain and discomfort, use of insulin in public 
places and parents’ own stress and anxiety. A larger sample 
size using a purpose-built validated tool would be required in 
future with possible inclusion of closed-loop system. 
However, this study identified a significant difference in 
parental confidence in avoiding severe hypoglycaemia when 
using fMDI. This finding could be utilized in the subgroup of 
parents who have a significant fear of hypoglycaemia 
impacting on their child’s glycaemic control. Accurate 
carbohydrate counting, and appropriate meal-time dose 
adjustment may be the key to success and can be difficult to 
achieve for some families. 
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Abbreviation 
T1D: type 1 diabetes mellitus, MDI: Multiple Daily 
Injection, CSII: Continuous Subcutaneous 
Insulin Infusion, fMDI: Flexible Multiple Daily Injection, 
HbA1c: Glycosylated hemoglobin,  
ITSQ: Insulin treatment satisfaction Questionnaire, DTSQ: 
Diabetes treatment satisfaction Questionnaire, SH: Severe 
Hypoglycaemia, DKA: Diabetic Ketoacidosis, CGM: 
Continuous Glucose Monitoring, HRQoL: Health Related 
Quality of Life, AP: Artificial Pancreatic System. 
Table 4. Diabetes Treatment Satisfaction Questionnaire Results. 
Item  
Overall 
Flexible Insulin 
Dosing 
Multiple Daily 
Insulin (MDI) 
Insulin Pump 
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
How satisfied are you with your child’s current treatment? *  34 4.9 (1.3) 10 5.6 (0.7) 14 
4.7 
(1.2) 
11 
4.3 
(1.5) 
How often have you felt that your child’s blood sugars have 
been unacceptably high recently? *  
34 3.3 (1.7) 10 3.9 (1.3) 14 
2.5 
(1.8) 
11 
3.4 
(1.6) 
How often have you felt that your child’s blood sugars have 
been unacceptably low recently? *  
34 2.3 (1.4) 10 3.2 (1.2) 14 
1.8 
(1.4) 
11 
2.0 
(1.3) 
How convenient have you been finding your child’s 
treatment to be recently?  
34 4.8 (0.9) 10 4.8 (0.9) 14 
4.8 
(1.0) 
11 
4.9 
(0.9) 
How flexible have you been finding your child’s treatment 
to be recently?  
34 4.8 (1.0) 10 4.7 (1.1) 14 
5.0 
(0.9) 
11 
4.7 
(1.2) 
Would you recommend your child’s type of treatment to 
someone else? *  
34 5.2 (1.1) 10 5.5 (0.7) 14 
4.6 
(1.4) 
11 
5.7 
(0.7) 
How satisfied would you be to continue with your child’s 
present form of treatment? *  
34 5.3 (0.9) 10 5.6 (0.5) 14 
4.8 
(1.1) 
11 
5.6 
(0.7) 
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